Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Foxo4-dri

Proxofim, FOXO4 D-Retro-Inverso peptide

Quick Stats
Studies 15
Trials 0
Score 3
2024 pubmed

Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia.

Jing. Xigang X; Jia. Shuang S; Teng. Maggie M; Day. Billy W BW; Afolayan. Adeleye J AJ; Jarzembowski. Jason A JA; Lin. Chien-Wei CW; Hessner. Martin J MJ; Pritchard. Kirkwood A KA; Naylor. Stephen S; Konduri. G Ganesh GG; Teng. Ru-Jeng RJ

Key Findings

  • Foxo4‑dri reduced markers of cellular senescence and improved lung structure in a rat model of hyperoxic bronchopulmonary dysplasia.
  • Senescent cells accumulated in multiple lung cell types, especially type 2 alveolar cells, after high‑oxygen exposure.
  • Both Foxo4‑dri and other compounds (TUDCA, KYC) that lower oxidative stress or ER stress gave comparable protective effects.

Practical Outcomes

  • For biohackers interested in senolytics, this work adds animal‑level evidence that Foxo4‑dri can clear senescent cells and improve tissue health. While the dosing schedule used in rat pups (intraperitoneal injections on days 4, 6, 8, and 10) isn’t directly translatable to humans, the results reinforce the potential of Foxo4‑dri as a tool for anti‑aging protocols. However, more human‑focused safety and dosing data are needed before practical application.

Summary

The study shows that a peptide called Foxo4‑dri, which blocks a protein interaction that keeps damaged cells alive, can reduce the buildup of senescent (aged) cells in the lungs of newborn rats exposed to very high oxygen levels. By clearing these senescent cells, the peptide helped the lungs develop more normally, similar to other drugs that lower oxidative stress. This supports the idea that Foxo4‑dri works as a senolytic in living animals.

Abstract

Oxidative stress, inflammation, and endoplasmic reticulum (ER) stress sequentially occur in bronchopulmonary dysplasia (BPD), and all result in DNA damage. When DNA damage becomes irreparable, tumor suppressors increase, followed by apoptosis or senescence. Although cellular senescence contributes to wound healing, its persistence inhibits growth. Therefore, we hypothesized that cellular senescence contributes to BPD progression. Human autopsy lungs were obtained. Sprague-Dawley rat pups exposed to 95% oxygen between Postnatal Day 1 (P1) and P10 were used as the BPD phenotype. <i>N</i>-acetyl-lysyltyrosylcysteine-amide (KYC), tauroursodeoxycholic acid (TUDCA), and Foxo4 dri were administered intraperitoneally to mitigate myeloperoxidase oxidant generation, ER stress, and cellular senescence, respectively. Lungs were examined by histology, transcriptomics, and immunoblotting. Cellular senescence increased in rat and human BPD lungs, as evidenced by increased oxidative DNA damage, tumor suppressors, GL-13 stain, and inflammatory cytokines with decreased cell proliferation and lamin B expression. Cellular senescence-related transcripts in BPD rat lungs were enriched at P10 and P21. Single-cell RNA sequencing showed increased cellular senescence in several cell types, including type 2 alveolar cells. In addition, Foxo4-p53 binding increased in BPD rat lungs. Daily TUDCA or KYC, administered intraperitoneally, effectively decreased cellular senescence, improved alveolar complexity, and partially maintained the numbers of type 2 alveolar cells. Foxo4 dri administered at P4, P6, P8, and P10 led to outcomes similar to TUDCA and KYC. Our data suggest that cellular senescence plays an essential role in BPD after initial inducement by hyperoxia. Reducing myeloperoxidase toxic oxidant production, ER stress, and attenuating cellular senescence are potential therapeutic strategies for halting BPD progression.

Study Information

Provider

pubmed

Year

2024

DOI

10.1165/rcmb.2023-0038oc